Novo Nordisk aims for FDA approval of weight loss pill

Injectable GLP1s have transformed millions of people's weight loss journeys. But the race to bring needlefree options to market now heating up as ompic maker Novo Nordisk demonstrated in a new study that its pill form can achieve similar efficacy finding over 64 weeks clinical trial participants lost 13.6% of their body weight and an estimated 16.6% if continued. Having this available with the same efficacy, the same safety that gives patients a choice and that will expand the number of patients that we can ...